Brain cancer drug trial halted after only two patients enrolled
NCT ID NCT03149575
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This Phase 3 trial aimed to test the drug VAL-083 in people with recurrent glioblastoma, an aggressive brain cancer, after standard treatments had failed. Participants were to receive either VAL-083 or another chemotherapy chosen by their doctor. However, the study was terminated early after enrolling only 2 out of a planned 180 participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Atlantic Neuroscience Institute - Brain Tumor Center of NJ
Summit, New Jersey, 07901, United States
-
Dent Neurosciences Research Center
Amherst, New York, 14226, United States
-
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, 90027, United States
-
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905, United States
-
University of California, San Francisco - Division of Neuro-Oncology
San Francisco, California, 94143, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VAL-083 (dianhydrogalactitol)
What this could lead to
If it had succeeded, this could have pointed toward a new treatment option for patients with recurrent glioblastoma who have run out of standard therapies.
What could go wrong
The trial was terminated early with only 2 participants enrolled, so no meaningful conclusions can be drawn. It is unclear if VAL-083 is effective or safe in this setting.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.